Join David D. Chism, MD, MS and Peter E. Clark from Vanderbilt-Ingram Cancer Center as they present their expertise on a range of cases pertaining to bladder cancer.

Join David D. Chism, MD, MS and Peter E. Clark from Vanderbilt-Ingram Cancer Center as they present their expertise on a range of cases pertaining to bladder cancer.

Although the standard of care for the treatment of advanced bladder cancer has remained mostly unchanged over the last 30 years, clinical trial data continue to provide insight into potential new therapies.

This educational initiative addresses healthcare professionals’ need to be educated on practice-changing developments in the management of advanced genitourinary cancers that have taken center stage in recent years.

This educational initiative addresses healthcare professionals’ need to be educated on practice-changing developments in the management of advanced genitourinary cancers that have taken center stage in recent years.

This information was originally presented at the NCCN 20th Annual Conference: Advancing the Standard of Cancer Care™ held in Hollywood, Florida.

Randomized trials support the use of neoadjuvant chemotherapy in muscle-invasive bladder cancer due to a noted survival advantage, which appeared to be strongly related to downstaging of the cancer to pT0 (complete pathologic response).

Bladder cancer is predominantly seen in elderly patients. With the aging United States population, the incidence and prevalence of bladder cancer are on the rise, heightening the relevance of this disease as a public health issue.

This archived webinar series is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Bladder, Kidney, and Prostate Cancers.

This archived webinar series is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Bladder, Kidney, and Prostate Cancers.